Results 201 to 210 of about 2,863,004 (297)

Patient-Reported Visual Function Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion

, 2019
Ingrid U. Scott, Paul VanVeldhuisen, Franca B. Barton, Neal L. Oden, Michael S. Ip, Barbara A. Blodi, Martin Worrall, Gary E. Fish, for the Study of Comparative Treatments for Retinal Vein Occlusion 2 Investigator Group   +8 more
openalex   +2 more sources

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

BMI and its association with patient-reported outcome measures following revision hip surgery. [PDF]

Bone Jt Open
Baumber R, Mehmood A, McCulloch R, Pereira SMP, Warwick E, Hart A, Moonesinghe SR, PQIP delivery team, PQIP collaborative, PQIP delivery team and collaborative, PQIP Delivery Team, Ramani Moonesinghe S, Wagstaff D, Bedford J, Sahni A, McGuckin D, Gilhooly D, Santos C, Wilson J, Martin P, Singleton G, Edwards K, Vindrola-Padros C, Warnakulasuriya S, Dorey J, Leemans I, Martinez D, Lourtie J, Baumber R, Dorey J, Swift A, Jackson A, Belete M, Warwick E, Argent M, Brooks R, Fulop N, Brent A, Williams K, Grocott M, Mythen M, Olive D, Taylor C, Drake S, Swart M, Bougeard AM, Bedford M, Vallance A, Singh P, Vohra R, Ignacka A, Tucker O, Aresu G, Cripps M, Ellicott H, Samuel K, Chazapis M, Hunt AF, Lusby E, Durrand J, Weerasuriya S, PQIP Collaborative, Batchelor A, Snowden C, Murray D, Evans E, Vaux E, Abercrombie J, McGhie J, Dhesi J, Clark T, Crossley A, McGrath J, Digner M, Hamilton M, Hill R, Shinde S, Brett S.   +77 more
europepmc   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Bridging the educational gap: a pilot study of integrating patient-reported outcome into orthopedic residency training. [PDF]

Front Med (Lausanne)
Huang L, Chen Y, Zhong Z, Zhu H, Hu H, Xu X.   +5 more
europepmc   +1 more source

Examining patient reported outcome measures for phantom limb pain: measurement use in a sample of Veterans with amputation [PDF]

Tonya L. Rich, Hannah Phelan, Amy Gravely, Kierra J. Falbo, Erin E. Krebs, Jacob A. Finn, Mary E. Matsumoto, Katherine Muschler, Jessica Kiecker, Andrew H. Hansen   +9 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Correction: Patient‑reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review

Systematic Reviews
Sally Taylor, Kate Law, Jake Coomber‑Moore, Michelle Davies, Fiona Thistlethwaite, Mel Calvert, Olalekan Aiyegbusi, Janelle Yorke   +7 more
doaj   +1 more source

Ethnic minority patients' experiences of filling in translated patient-reported outcome measures. [PDF]

J Public Health Res
Alpers LM, Hanssen I.
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source